CALIPSO Trial
Cross-source consensus on CALIPSO Trial from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Comparisons
Other
Other
Other
Highlighted claims
- The CALIPSO trial tests whether shorter antimicrobial prophylaxis durations after cardiac surgery are clinically acceptable compared with longer durations. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol
- CALIPSO compares intraoperative-only prophylaxis, 24 hours of postoperative cefazolin, and 48 hours of postoperative cefazolin. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol
- The trial is an international multicentre adaptive pragmatic double-blind placebo-controlled phase IV randomized non-inferiority trial. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol
- The trial plans to enrol 9180 patients across Australia and other international sites. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol
- Recruitment began in February 2023 and is planned to continue until December 2027. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol